Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Imugene ( (AU:IMU) ) just unveiled an announcement.
Imugene chief executive Leslie Chong has increased her direct holding in the company, acquiring 65,053 ordinary fully paid shares on market at A$0.145 per share. Following the transaction, her direct stake has risen to 2,683,835 shares, while her indirect holdings and equity-based incentives, including options and performance rights, remain unchanged, signaling continued alignment with shareholders.
The on-market purchase consolidates Chong’s financial exposure to Imugene’s future performance without altering existing option or performance-right structures. The move may be viewed by investors as a vote of confidence in the company’s strategic direction and prospects, although no additional changes to director interests in contracts or trading during closed periods were disclosed.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.82 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene Limited is a biotechnology company focused on developing immuno-oncology therapies, including novel cancer treatments that leverage the immune system. The company operates in the biopharmaceutical sector and is listed on the ASX, attracting investors interested in innovative cancer drug development and related clinical programs.
Average Trading Volume: 1,535,728
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$51.77M
See more data about IMU stock on TipRanks’ Stock Analysis page.